Oscar Health Inc OSCR.N, OSCR.K is expected to show a rise in quarterly revenue when it reports results on November 6 for the period ending September 30 2025
The New York City-based company is expected to report a 27.2% increase in revenue to $3.082 billion from $2.42 billion a year ago, according to the mean estimate from 8 analysts, based on LSEG data.
LSEG's mean analyst estimate for Oscar Health Inc is for a loss of 56 cents per share.
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy," 4 "hold" and 5 "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Oscar Health Inc is $13.00, about 35.8% below its last closing price of $17.66
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2025 | -0.86 | -0.46 | -0.89 | Missed | -92.3 |
Mar. 31 2025 | 0.79 | 0.79 | 0.92 | Beat | 16.1 |
Dec. 31 2024 | -0.59 | -0.59 | -0.62 | Missed | -5.1 |
Sep. 30 2024 | -0.18 | -0.17 | -0.22 | Missed | -28.3 |
Jun. 30 2024 | 0.17 | 0.16 | 0.20 | Beat | 23.7 |
Mar. 31 2024 | 0.27 | 0.27 | 0.62 | Beat | 127.9 |
Dec. 31 2023 | -0.73 | -0.72 | -0.66 | Beat | 8.7 |
Sep. 30 2023 | -0.47 | -0.47 | -0.29 | Beat | 38.6 |
This summary was machine generated November 4 at 15:10 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)